VA
VR Adviser Portfolio holdings
AUM
$1.33B
This Quarter Return
-2.68%
1 Year Return
+6.92%
3 Year Return
+862.77%
5 Year Return
+1,580.48%
10 Year Return
–
AUM
$732M
AUM Growth
+$732M
(-6%)
Cap. Flow
+$60.5M
Cap. Flow
% of AUM
8.27%
Top 10 Holdings %
Top 10 Hldgs %
70.9%
Holding
29
New
3
Increased
6
Reduced
5
Closed
3
Top Buys
| 1 |
Viridian Therapeutics
VRDN
|
$36.2M |
| 2 |
LIAN
LianBio American Depositary Shares
LIAN
|
$33.1M |
| 3 |
TCDA
Tricida, Inc. Common Stock
TCDA
|
$29.7M |
| 4 |
KDNY
Chinook Therapeutics, Inc. Common Stock
KDNY
|
$20.9M |
| 5 |
Relmada Therapeutics
RLMD
|
$19.9M |
Top Sells
| 1 |
Altimmune
ALT
|
$43M |
| 2 |
Cullinan Oncology
CGEM
|
$15.9M |
| 3 |
KNTE
Kinnate Biopharma Inc. Common Stock
KNTE
|
$12.4M |
| 4 |
Pharvaris
PHVS
|
$9.8M |
| 5 |
Celldex Therapeutics
CLDX
|
$9.01M |
Sector Composition
| 1 | Healthcare | 95.32% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
26
Corvus Pharmaceuticals
CRVS
$419M
| $603K | 0.08% |
250,000
-3,177,461
| -93% | -$7.66M |
|
|
27
Altimmune
ALT
$325M
| – | – |
-3,800,000
| Closed | -$43M |
|
|
28
Cullinan Oncology
CGEM
$456M
| – | – |
-706,050
| Closed | -$15.9M |
|
|
29
Pharvaris
PHVS
$1.41B
| – | – |
-552,882
| Closed | -$9.8M |
|